Chemotherapy induced liver toxicity in children with malignant diseases

1. Grigorian A., O’Brien C.B. – Hepatotoxicity Secondary to Chemotherapy. Journal of Clinical and Translational Hepatology, 2014, 2:95-102.10.14218/JCTH.2014.00011452126526357620Search in Google Scholar

2. Stirnimann G., Kessebohm K., Lauterburg B. – Liver injury caused by drugs: an update. Swiss Med Wkly 2010, 140:w13080.10.4414/smw.2010.1308020927685Search in Google Scholar

3. Xie C., Yue L.J., Ding H., et al. – Correlations between 6-mercaptopurine treatment-related adverse reactions in children with acute lymphoblastic leukemia and polymorphisms of thiopurine methyltransferase gene. Zhongguo Dang Dai Er Ke Za Zhi, 2014, 16(5):499-503.24857000Search in Google Scholar

4. Sharifi M.J., Bahoush G., Zaker F., et al. – Association of -24CT, 1249GA, and 3972CT ABCC2 gene polymorphisms with methoterxate serum levels and toxic side effects in childern with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2014, 31(2):169-77.10.3109/08880018.2013.87062524552501Search in Google Scholar

5. Chen B., Xian Y., Su Y.C., et al. – A clinical study of drug-related toxicities of CCLG-ALL 08 protocol for childhood acute lymphoblastic leukemia. Zhongguo Dang Dai Er Ke Za Zhi, 2013, 15(9):737-42.24034915Search in Google Scholar

6. Rawat D., Gillett P.M., Devadason D., et al. – Long-term follow-up of children with 6-thioguanine-related chronic hepatotoxicity following treatment for acute lymphoblastic leukemia. J Pediatr Gastroenterol Nutr, 2011, 53(5):478-9.2170140710.1097/MPG.0b013e31822960e921701407Search in Google Scholar

7. Ravikumara M., Hill F.G., Wilson D.C., et al. – 6-Thioguaninerelated chronic hepatotoxicity and variceal haemorrhage in children treated for acute lymphoblastic leukemia - a dual-centre experience. J Pediatr Gastroenterol Nutr, 2006, 42(5):535-8.10.1097/01.mpg.0000221901.76404.0716707977Open DOISearch in Google Scholar

8. Ebbesen M.S., Nygaard U., Rosthoj S., et al. – Hepatotoxicity During Maintenance Therapy and Prognosis in Children with Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol, 2017, 39(3):161-166.10.1097/MPH.000000000000073328060115Search in Google Scholar

9. Schmiegelow K., Pulczynska M. – Prognostic significance of hepatotoxicity during maintenance chemotherapy for childhood acute lymphoblastic leukaemia. Br J Cancer, 1990, 61(5):767-72.10.1038/bjc.1990.17219716072337515Open DOISearch in Google Scholar

10. Ballauff A., Krahe J., Jansen B., et al. – Chronic liver disease after treatment of malignancies in children. Klin Pediatr, 1999, 211(2):49-52.10.1055/s-2008-104376310407809Search in Google Scholar

11. Elbarbary N.S., Ismail E.A., Farahat R.K., et al. – ω-3 fatty acids as an adjuvant therapy ameliorates methotrexateinduced hepatotoxicity in childern and adolescents with acute lymphoblastic leukemia: A randomized placebo-controlled study. Nutrition, 2016, 32(1):41-7.10.1016/j.nut.2015.06.01026421385Search in Google Scholar

12. Hagag A.A., AbdElaal A.M., Elfaragy M.S., et al. – Therapeutic value of black seed oil in methotrexate hepatotoxicity in Egyptian children with acute lymphoblastic leukemia. Infect Disord Drug Targets, 2015, 15(1):64-71.10.2174/187152651566615032016144025809628Search in Google Scholar

13. Ahmad A., Husain A., Mujeeb M., et al. – A review on therapeutic potential of Nigella sativa: A miracle herb. Asian Pac J Trop Biomed, 2013, 3(5):337-352.10.1016/S2221-1691(13)60075-1Search in Google Scholar

14. Ladas E.J., Kroll D.J., Oberlies N.H., et al. – A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia. Cancer, 2010, 116(2):506-13.10.1002/cncr.24723Search in Google Scholar

15. Mohammed S.M., Farid S.F., Khaleel S.A., et al. – Hepatoprotective efficacy of ursodeoxycholic acid in pediatrics acute lymphoblastic leukemia. Pediatr Hematol Oncol, 2012, 29(7):627-32.10.3109/08880018.2012.713083Search in Google Scholar

16. Andrade R.J., Lucena M.I., Fernandez M.C., et al. – Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005, 129:512.10.1016/j.gastro.2005.05.006Search in Google Scholar

17. Bjornsson E. – Drug-induced liver injury Hy’s rule revisited. Clin Pharmacol Ther. 2006, 79:521.10.1016/j.clpt.2006.02.012Open DOISearch in Google Scholar

18. Ostapowicz G., Fontana R.J., Schiedt F.U., et al.- Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med, 2002, 137:947.10.7326/0003-4819-137-12-200212170-00007Search in Google Scholar

19. O’Grady J.G., Alexander G.J., Hayllar K.M., et al.- Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989, 97:439.10.1016/0016-5085(89)90081-4Open DOISearch in Google Scholar

20. Bjornsson E., Davidsdottir L.- The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol 2009, 50:511.10.1016/j.jhep.2008.10.02119155082Open DOISearch in Google Scholar